Skin test categories | Baseline | Follow-up (6Â months) | p value |
---|---|---|---|
n (%) | n (%) | ||
Proportion of anergic | |||
 Post-SAM (n = 93/86) | 83 (89.2) | 79 (92.0) | 0.551 |
 Community control (n = 94/89) | 90 (95.7) | 84 (94.4) | 0.742 |
 p value | 0.091 | 0.604 |  |
Proportion with any induration | |||
 Post-SAM (n = 93/86) | 10 (10.8) | 7 (8.0) | 0.551 |
 Community control (n = 94/89) | 4 (4.3) | 5 (5.6) | 0.742 |
 p value | 0.091 | 0.604 |  |
Positive test (induration ≥ 10 mm) | |||
 Post-SAM (n = 93/86) | 3 (3.2) | 6 (7.0) | 0.316 |
 Community control (n = 94/89) | 2 (2.1) | 3 (3.4) | 0.676 |
 p value | 0.682 | 0.324 |  |
Skin test categories | Baseline | Follow-up (6Â months) | p value |
---|---|---|---|
Mean ± SD | Mean ± SD | ||
Average diameter of induration | |||
 Post-SAM (n = 10/7) | 10.2 ± 9.8 | 14.9 ± 4.4 | 0.256 |
 Community control (n = 4/5) | 7.7 ± 6.4 | 11.2 ± 3.5 | 0.327 |
 p value | 0.648 | 0.150 |  |
Average induration for positive test | |||
 Post-SAM (n = 3/6) | 21.7 ± 1.0 | 15.9 ± 3.9 | 0.044 |
 Community control (n = 2/3) | 13.0 ± 3.5 | 13. 7 ± 1.0 | 0.748 |
 p value | 0.398 | 0.376 |  |